
G1 Therapeutics GTHX
Quarterly report 2024-Q2
added 08-08-2024
G1 Therapeutics Interest Expense 2011-2026 | GTHX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense G1 Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.32 M | -9.68 M | -4.97 M | -1.37 M | 6.59 M | 4 M | 847 K | 100 K | -4.84 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.59 M | -9.68 M | -1.63 M |
Quarterly Interest Expense G1 Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.93 M | -1.17 M | - | -931 K | -1.5 M | -1.85 M | - | -2.5 M | -2.48 M | -2.41 M | -2.19 M | -1 M | -1.01 M | -769 K | -780 K | -998 K | -388 K | 798 K | 1.11 M | 1.66 M | 1.89 M | 1.93 M | 1.99 M | 904 K | 785 K | 315 K | 301 K | 328 K | 185 K | 33 K | 2 K | 56 K | 50 K | -8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.99 M | -2.5 M | -299 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.56 | - | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
1.89 M | $ 3.13 | - | $ 229 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Ascendis Pharma A/S
ASND
|
80.6 M | $ 231.03 | 2.23 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.61 | - | $ 8.69 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 6.63 | - | $ 182 M | ||
|
BioCardia
BCDA
|
3 K | $ 1.27 | - | $ 26.9 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
103 K | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Biosciences
CBIO
|
-1.5 M | $ 11.58 | - | $ 1.03 B | ||
|
Cerus Corporation
CERS
|
3.02 M | $ 1.8 | 6.51 % | $ 343 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 90.54 | - | $ 27.2 B | ||
|
AVEO Pharmaceuticals
AVEO
|
1.6 M | - | - | $ 521 M | ||
|
CNS Pharmaceuticals
CNSP
|
7.03 K | $ 2.45 | 0.41 % | $ 936 K | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.64 | - | $ 16.6 M | ||
|
Cardiff Oncology
CRDF
|
5 K | $ 1.9 | - | $ 127 M | ||
|
CorMedix
CRMD
|
34.3 K | $ 6.54 | - | $ 471 K | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.51 | - | $ 385 M |